When Biogen was founded in 1978, it had a simple, research-centered business model: its scientists would use biotechnology to discover compounds that might be used to create new drugs, and then it would license those compounds to big pharmaceutical companies. It had no need to build a manufacturing or distribution infrastructure because it didn’t intend to actually produce drugs.
A version of this article appeared in the May–June 2000 issue of Harvard Business Review.
